Bench2Bedside spoke with GuideStar CEO Mike Dolphin, Ph.D., about the overlooked burden of accidental dural puncture, and how his outsider’s perspective as an aerospace engineer helped him challenge a long-standing standard of care, leading to the development of EpiZact....
Bench2Bedside spoke with ARC Medical CEO Chris Springate about the limitations of existing adhesion barriers, the company’s differentiated approach, and the clinical programs underway to evaluate its technology in orthopedic and abdominopelvic surgery....
Bench2Bedside spoke with Steven Damon, CEO of Micron Biomedical about the companies “push button”, needle-free drug delivery technology, and how it can bring life-saving medicines and vaccines to some of the world’s most remote regions....
Bench2Bedside recently sat down with Eileen Heffernan, Celltaxis' Chief Executive Officer and co-founder, to discuss the Company's mission to transform the treatment of lymphatic disease, the science behind its therapeutic approach, and why she believes Celltaxis is uniquely positioned to...
In this Bench2Bedside conversation, we speak with CEO Andrew Hall about Consano Bio’s transition into the clinic, marked by first patient dosed in its Phase 1 study, and the implications for treating nerve-related pain....
In this interview, with Bench2Bedside, Dr. Haifeng Chen, CEO of AAVivo, Inc., discusses how his company aims to bypass these hurdles. By shifting from a manufacturing mindset to an engineering one, Dr. Chen outlines a revolutionary vision to turn the...
In this Bench2Bedside conversation, Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, discusses the company’s recent Nasdaq direct listing, the value potential of its Bisphosphocin® antimicrobial platform, and its lead candidate Nu-3 for mildly infected diabetic foot ulcers (iDFU)....
In this Bench2Bedside conversation, Enveric’s CEO, Joseph Tucker, Ph.D., discusses the company’s lead candidate, EB-003, the potential of dual-receptor engagement, and the hope of bringing solutions to difficult-to-treat mental health disorders....
As the New Year kicks off and the biotech world makes the annual pilgrimage to San Francisco, Michael Brinkman, Managing Director at Jefferies, gives his views on the unusually strong biotech and specialty pharma market moving into 2026....
Adcytherix is redefining the antibody-drug conjugate (ADC) landscape with a focus on payload innovation, conjugation precision, and antibody engineering. While most ADCs rely on a narrow set of cytotoxic payloads, Adcytherix’s proprietary payload families are designed to overcome resistance, improve...
Leo Cancer Care is working to provide an improved patient experience and efficacy with upright radiation therapy solutions that are designed for a wider variety of healthcare settings. Here, CEO Stephen Towe explains how their solutions will invert the long-held...
Maxwell Biosciences is pioneering a new category of therapeutics called Claromers®—synthetic small molecules designed to exploit the unique weaknesses of pathogenic microorganisms without relying on mechanisms that drive resistance. ...
Tikva Allocell is developing breakthrough cancer treatments using its proprietary empowered ALLO EBVST (Epstein-Barr Virus) platform, which utilizes highly specific, second-generation, allogeneic Virus-Specific T cells (VSTs) ...
KROMATID is carving a unique role with its single-cell structural analysis platform. While many labs offer broad services, KROMATID focuses on high-resolution visualization of structural variants that can make or break IND and BLA filings. ...
Perfusion Medical is an emerging biopharmaceutical company developing life-saving, acute cardiovascular therapies to transform the treatment of acute kidney injury (AKI) and hemorrhagic shock—two high-value, underserved indications with limited innovation. ...
GlycoNex is advancing a new generation of glycan-directed antibody-drug conjugates (ADCs) aimed at improving precision in solid tumor treatment. While many ADCs target well-known protein markers, GlycoNex focuses on tumor-associated glycans, carbohydrate structures overexpressed on cancer cells but largely absent...
Linda Pullan, Ph.D., of Pullan Consulting, has been working with biopharma business development executives for more than two decades, offering her expertise to help companies find and negotiate deals, from evaluations to research collaborations to licenses to co-development, and acquisitions....
Medication nonadherence is one of the most persistent challenges in modern healthcare, driving up costs and compromising outcomes across chronic disease categories. Enter Adhere+, a SaaS-based platform that enables providers to monitor and support patients’ care plan adherence through the...
Elysium Therapeutics is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, such as fentanyl. In this installment of Bench2Bedside, Elysium’s CEO Greg Sturmer discusses the need for improved rescue medicines...
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. In this installment of Bench2Bedside, CEO Francisco Salva discusses the company’s two lead programs, ATR-12 and ATR-04, developed from a proprietary platform of engineered...